基于p53蛋白的抗肿瘤治疗策略研究进展  

Research progress in anti-tumor treatment strategies based on p53 protein

作　　者：张涵 李文芳 Zhang Han;Li Wenfang(School of Pharmaceutical Sciences and Institute of Materia Medica,Xinjiang University,Urumqi 830046,China)

机构地区：[1]新疆大学药学院,新疆大学药物研究所,乌鲁木齐830046

出　　处：《国际生物医学工程杂志》2024年第5期504-512,共9页International Journal of Biomedical Engineering

基　　金：国家自然科学基金(32471260);新疆维吾尔自治区自然科学基金(2023D01C202)。

摘　　要：p53蛋白是一种关键的转录因子和肿瘤抑制因子,其在细胞应激反应时被激活,通过修复或清除受损细胞,从而防止细胞发生癌变。p53蛋白在超过50%的恶性肿瘤中发生突变,是目前已知与肿瘤发生发展相关性最高的蛋白之一。恢复p53蛋白的肿瘤抑制功能一直是抗肿瘤研发的重要方向,近年来已有多款基于p53蛋白的抗肿瘤治疗策略进入临床试验阶段并取得良好成效。从p53蛋白的结构功能与调控入手,主要总结了基于p53蛋白的抗肿瘤治疗策略研究进展,包括恢复mutp53蛋白功能、降解mutp53蛋白、靶向p53蛋白的负调控因子,以及基于p53蛋白的免疫疗法和基因疗法,旨在为后续研究者提供新的创新思路。The p53 protein is a key transcription factor and tumor suppressor,which activates in cellular stress response and prevents the cell malignant transformation by repairing or eliminating damaged cells.The p53 protein is mutated in more than 50%of malignant tumors,and is one of the proteins known to have the highest correlation with tumorigenesis and development.Restoring the tumor suppressor function of p53 protein has always been an important direction of anti-tumor research and development.In recent years,several anti-tumor treatment strategies based on p53 protein have entered the clinical trial stage and achieved promising efficacy.In this review,starting from the structure,function,and regulation of p53 protein,the research progress in anti-tumor treatment strategies based on p53 protein was summarized,including restoration of the function of mutp53 protein,degradation of mutp53 protein,targeting of the negative regulators of p53 protein,as well as immunotherapy and gene therapy based on p53 protein,with the aim of providing new innovative ideas for the subsequent researchers.

关 键 词：P53蛋白 TP53基因 鼠双微体同源基因2 鼠双微体同源基因4 抗肿瘤 治疗策略 

分 类 号：R730.5[医药卫生—肿瘤]